Agreement accelerates Novartis’ ability to use data and digital to transform commercial models, ensuring more meaningful interactions with healthcare providers NEW YORK & WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 24, 2018-- SHYFT Analytics , a Medidata Solutions (NASDAQ:MDSO) company, announced today
China Drug Administration and Celltrion Lead Keynote Sessions SHANGHAI --(BUSINESS WIRE)--Jul. 11, 2018-- This week, the Asia Pacific segment of Medidata’s (NASDAQ:MDSO) global NEXT series continues with customer events in Seoul and Shanghai . Sessions will explore trends in virtual trials, mobile
NEW YORK --(BUSINESS WIRE)--Jul. 10, 2018-- Medidata (NASDAQ:MDSO), today announced that it will release its second quarter 2018 financial results before the open of the market on Tuesday, July 24, 2018 . The Company will also hold a conference call at 8:00 a.m.
Accelerating Innovation and Adoption for Industry Leading eClinical Platform SHANGHAI --(BUSINESS WIRE)--Jun. 28, 2018-- With China based customers doubling in 2017, Medidata (NASDAQ: MDSO) announced the appointment of Jim (Hui) Xu as general manager in the market, and plans to double the size of
Patient Burden Index uses data-driven approach to provide objective insight when creating trial protocols to improve study retention and recruitment NEW YORK --(BUSINESS WIRE)--Jun. 25, 2018-- To make clinical research truly patient-centric, Medidata (NASDAQ: MDSO) announced the launch of the
Leading the digital transformation of life sciences with artificial intelligence and advanced analytics NEW YORK --(BUSINESS WIRE)--Jun. 12, 2018-- Medidata (NASDAQ:MDSO) today announced that it has entered into a definitive agreement to acquire SHYFT Analytics , bringing the leading platform for
Pancreatic Cancer Research Exemplifies Increasing Use of Genomic Data for Precision Medicine NEW YORK --(BUSINESS WIRE)--May 23, 2018-- Medidata (NASDAQ: MDSO) announced that Memorial Sloan Kettering Cancer Center (MSK) is using Rave Omics with Biomarker Discovery for patients with pancreatic
Integration of Genomic and Clinical Trial Data Enables Biomarker Hypothesis Generation by Clinical Development NEW YORK --(BUSINESS WIRE)--May 21, 2018-- For the second consecutive year, Medidata (NASDAQ:MDSO) will be presenting its pioneering analytics innovation during the 2018 ASCO Annual
Innovative Biotech Company Adopts Medidata Rave EDC, Benefiting From a Unified Platform for All Phases of the Study NEW YORK --(BUSINESS WIRE)--May 17, 2018-- Biotech company, PhaseBio Pharmaceuticals , has become Medidata’s (NASDAQ:MDSO) 1,000th customer.